VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.14%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$204M
AUM Growth
+$15.9M
(+8.5%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
8.1%
Top 10 Holdings %
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40
Top Buys
| 1 |
CrowdStrike
CRWD
|
$1.1M |
| 2 |
Netflix
NFLX
|
$1.03M |
| 3 |
Qualcomm
QCOM
|
$1.03M |
| 4 |
Royal Caribbean
RCL
|
$1M |
| 5 |
TJX Companies
TJX
|
$973K |
Top Sells
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.11M |
| 2 |
Eli Lilly
LLY
|
$937K |
| 3 |
Freeport-McMoran
FCX
|
$933K |
| 4 |
Align Technology
ALGN
|
$933K |
| 5 |
Martin Marietta Materials
MLM
|
$930K |
Sector Composition
| 1 | Financials | 26.66% |
| 2 | Healthcare | 19.14% |
| 3 | Technology | 17.16% |
| 4 | Energy | 7.21% |
| 5 | Industrials | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Regenxbio
RGNX
$490M
| $81K | 0.04% |
6,921
+2,762
| +66% | +$32.3K |
|
402
Liquidia Corp
LQDA
$2.48B
| $80.9K | 0.04% |
6,741
-5,144
| -43% | -$61.7K |
|
403
AbCellera Biologics
ABCL
$1.26B
| $80.5K | 0.04% |
27,185
+11,373
| +72% | +$33.7K |
|
404
Xencor
XNCR
$610M
| $80.4K | 0.04% |
4,248
+161
| +4% | +$3.05K |
|
405
Applied Therapeutics
APLT
$68.2M
| $80.4K | 0.04% |
+17,210
| New | +$80.4K |
|
406
Scholar Rock
SRRK
$3.02B
| $80K | 0.04% |
9,600
+4,929
| +106% | +$41.1K |
|
|
VERV
407
DELISTED
Verve Therapeutics
VERV
| $78.9K | 0.04% |
16,165
+10,119
| +167% | +$49.4K |
|
|
CMPS
408
Compass Pathways
CMPS
$493M
| $78.8K | 0.04% |
13,044
+1,823
| +16% | +$11K |
|
409
Olema Pharmaceuticals
OLMA
$570M
| $78.6K | 0.04% |
7,265
+235
| +3% | +$2.54K |
|
410
Neurogene
NGNE
$285M
| $78.5K | 0.04% |
+2,156
| New | +$78.5K |
|
|
IGMS
411
DELISTED
IGM Biosciences
IGMS
| $78.3K | 0.04% |
11,401
-1,931
| -14% | -$13.3K |
|
412
89bio
ETNB
$1.32B
| $78K | 0.04% |
9,744
+1,706
| +21% | +$13.7K |
|
413
Intellia Therapeutics
NTLA
$1.29B
| $78K | 0.04% |
3,487
+768
| +28% | +$17.2K |
|
414
4D Molecular Therapeutics
FDMT
$340M
| $77.9K | 0.04% |
3,709
-1,506
| -29% | -$31.6K |
|
415
Perspective Therapeutics
CATX
$257M
| $77.8K | 0.04% |
+7,803
| New | +$77.8K |
|
416
Vir Biotechnology
VIR
$732M
| $77.8K | 0.04% |
8,738
+108
| +1% | +$961 |
|
417
Kymera Therapeutics
KYMR
$3.11B
| $77.5K | 0.04% |
2,596
-811
| -24% | -$24.2K |
|
418
Terns Pharmaceuticals
TERN
$632M
| $77.3K | 0.04% |
11,344
-2,028
| -15% | -$13.8K |
|
419
uniQure
QURE
$985M
| $77.2K | 0.04% |
17,243
+6,550
| +61% | +$29.3K |
|
420
Editas Medicine
EDIT
$248M
| $77K | 0.04% |
16,489
+8,499
| +106% | +$39.7K |
|
421
CureVac
CVAC
$1.21B
| $76.9K | 0.04% |
22,631
+7,643
| +51% | +$26K |
|
422
Relay Therapeutics
RLAY
$710M
| $75.4K | 0.04% |
11,569
+2,867
| +33% | +$18.7K |
|
|
BCYC
423
Bicycle Therapeutics
BCYC
$496M
| $75.4K | 0.04% |
3,725
-2,049
| -35% | -$41.5K |
|
424
Annexon
ANNX
$238M
| $73.8K | 0.04% |
+15,063
| New | +$73.8K |
|
425
Tyra Biosciences
TYRA
$674M
| $72.9K | 0.04% |
+4,560
| New | +$72.9K |
|